Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and Carboplatin in Extensive Stage Small Cell Lung Cancer
NCT00454324Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2006
- Primary completion
- Jul 2010
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in small cell lung cancer (SCLC) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 12 weeks. Started Apr 2006; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00454324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454324.